PatientsVille.com Logo

HYPONATRAEMIA and Simvastatin

PatientsVille

HYPONATRAEMIA Symptoms and Causes

Table salt is a combination of two minerals - sodium and chloride Your body needs some sodium to work properly. It helps with the function of nerves and muscles. It also helps to keep the right balance of fluids in your body. Your kidneys control how much sodium is in your body. If you have too much and your kidneys can't get rid it, sodium builds up in your blood. This can lead to high blood pressure. High blood pressure can lead to other health problems.

Most people in the U.S. get more sodium in their diets than they need. A key to healthy eating is choosing foods low in sodium. The Dietary Guidelines recommend that most adults eat less than 2.3 grams per day. That equals about 1 teaspoon of table salt a day. Some people are more sensitive to the effects of salt than others and should eat less. This includes people who have high blood pressure, diabetes, or kidney problems, or are African-American or over age 50. Reading food labels can help you see how much sodium is in prepared foods.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for HYPONATRAEMIA

HYPONATRAEMIA treatment research studies

Simvastatin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Simvastatin Side Effects

Rhabdomyolysis (1169)
Myalgia (1039)
Renal Failure Acute (504)
Fatigue (491)
Blood Creatine Phosphokinase Increased (489)
Pain In Extremity (449)
Muscular Weakness (445)
Asthenia (394)
Arthralgia (375)
Muscle Spasms (346)
Pain (328)
Dyspnoea (311)
Dizziness (304)
Nausea (281)
Fall (261)
Diarrhoea (257)
Gait Disturbance (243)
Alanine Aminotransferase Increased (241)
Headache (240)
Myositis (238)
Malaise (187)
Myopathy (180)
Back Pain (166)
Amnesia (163)
Vomiting (160)
Insomnia (157)
Depression (156)
Rash (154)
Aspartate Aminotransferase Increased (152)
Renal Failure (143)
Liver Function Test Abnormal (141)
Abdominal Pain (140)
Chest Pain (134)
Blood Creatinine Increased (133)
Confusional State (130)
Paraesthesia (126)
Hypoaesthesia (126)
Feeling Abnormal (123)
Memory Impairment (122)
Anxiety (117)
Myocardial Infarction (112)
Weight Decreased (111)
Pruritus (107)
Cough (107)
Condition Aggravated (106)
Cerebrovascular Accident (104)
Tendon Rupture (103)
Hepatic Enzyme Increased (101)
Mobility Decreased (98)
Abasia (98)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I been on simastatin 20gms for 4 yrs. I remember I did had a rash last Aug 09 and it was realy itch. After 2 wks of suffering. I finally made Appt. with my Dr.. They schelule me for the following week. The day I planed t

:(vvery dissy imsoniac light headness.................. =-O

A few months ago my doctor prescribed 40mg simvastatin to take one before bedtime ,and he never told me anything about the side efect of thid drug,I have started feeling some muscle pain and abdomnel paint that was later on after I started taking the

Blurred vision, like I was looking through water around the outside of my eyes, then very dizz, faint but not fainting--this has happened twice, I was shaky and weak after--it was frightening.....

Extreme muscle pain in legs, shoulders, neck and back. already had fibromyalgia and this was worse than any pain had previous to taking simvastatin. I was on it a yr. I had chonic insomnia, chest pain like pneumonia, so tired couldn't hardly move. co

Hair loss

Has anyone taking this medication after a year,expierenced headaches?

Have been on Zocor for almost 10 years with no problems but 6 months ago started getting rash on my left side which seems to be less annoying with good skin lotion. I also take some vitamin pills that have 1000% niacin(for building good HDL) and Niac

I am taking 40 mg of simvaststin and my hair is really falling out bad. it stated this after i've been on the drug for awhile. should i stop taking it to see will my hair stop coming out from the root?

I can certainly sympathize. I began taking 40mg dose of Zocor inNovember of 2009 three days a week. Took for 6 months. Had blood work done in March. Cholesterol level dropped to 206. Doctor

I took Trileptal for about a week. I then was diagnosed with hyponatraemia and was hospitalized for 3 days. This was one of the most scary experiences in my life - I thought I was dying :'(

That seems pretty quick for hyponatraemia to be induced, but everyone is different. At first you may expect a headache and it may take a month or more to tolerate it, if you can. I don't think that it's for me. If you ever get really intoxicated

HYPONATRAEMIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia
Conditions: Euvolemic Hyponatremia;   Hypervolemic Hyponatremia
Intervention:
Outcome Measures: Change in serum sodium concentration from beginning of treatment period to the end of treatment period or discharge for a given hyponatremia treatment;   Duration of hospital stay from time of first presentation of hyponatremia (which will be taken as the time of first presentation of hyponatremia for the current admission) to discharge;   Time to initiation of hyponatremia treatment;   Relative proportions of etiologies associated with hyponatremia;   Profile of investigations performed in diagnosing hyponatremia;   Therapies used in the management of hyponatremia;   Effectiveness of individual therapies in correcting hyponatremia and time taken to achieve the correction.;   Effectiveness of individual therapies in achieving symptom improvement measured as the number of reported symptoms at the start and end of treatment with a specific therapy;   Medically necessary length of hospital stay and duration of intensive care unit (ICU) stay;   Impact of hyponatremia on medically necessary length of stay
2 Recruiting Fractional Urate Excretion in Nonedematous Hyponatremia
Conditions: Cerebral Hyponatremia;   SIADH;   Cerebral Salt-wasting Syndrome;   Reset Hypothalamic Osmostat
Intervention: Drug: Tolvaptan in euvolemic hyponatremia
Outcome Measure: Etiologic categorization of nonedematous hyponatremia
3 Recruiting Institutional Registry of Hyponatremia
Condition: Hyponatremia
Intervention:
Outcome Measure: clinical features
4 Recruiting Characterisation of Neuropsychological and Motoric Performance in Patients With Hyponatremia
Condition: Hyponatremia
Intervention: Other: Neuropsychological and motoric tests
Outcome Measure: Assessment of Performance in individual tests
5 Recruiting Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Condition: Hyponatremia
Interventions: Drug: Tolvaptan;   Drug: Placebo;   Behavioral: Hepatic Encephalopathy Assessment;   Behavioral: Quality of Life Assessment;   Biological: Vital signs;   Biological: Blood laboratory tests;   Procedure: Ascites Evaluation;   Procedure: Edema
Outcome Measures: Length of Hospital Stay;   Severity of Hepatic Encephalopathy;   Ascites;   Renal function [BUN and creatinine laboratory results];   Hospital Readmission Rate;   Survival;   Neutrophil function [results from the assay of neutrophils];   Tolerability of diuretic therapy
6 Not yet recruiting Relationship Between Heat Wave and Hyponatremia
Condition: Hyponatremia
Intervention: Other: Seasonality
Outcome Measures: Number of patients with moderate to severe hyponatremia;   Mortality;   Hospital length of stay
7 Unknown  Radiocontrast Media Induced Hyponatremia
Condition: Percutaneous Coronary Intervention
Intervention:
Outcome Measures: Incidence of contrast media induced translocational hyponatremia;   Renal function is affected by the incidence of translocational hyponatremia.
8 Unknown  Establishment of an Algorithm for a Clinical Classfication of Hypoosmolar Hyponatremia
Condition: Hyponatremia
Intervention:
Outcome Measure: Establishment of an clinical algorithm to differentiate the different causes of hyponatremia
9 Not yet recruiting An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
Condition: Hyponatremia
Intervention: Drug: Tolvaptan
Outcome Measures: Adverse Events, including cases of dehydration.;   Vital signs of potential clinical relevance - Mean change from baseline to study completion.;   Body weight of potential clinical relevance - Mean change from baseline to study completion.;   Height of potential clinical relevance - Mean change from baseline to study completion.;   Growth percentiles of potential clinical relevance - Mean change from baseline to study completion.;   Tanner stages of potential clinical relevance - Mean change from baseline to study completion.;   Change in serum sodium from baseline at each visit while IMP is being administered.;   Plasma concentrations of tolvaptan and metabolites in subjects who have continued tolvaptan therapy for 8 consecutive weeks.
10 Unknown  Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Condition: Non-hypovolemic Non-acute Hyponatremia
Interventions: Drug: Tolvaptan;   Drug: Placebo
Outcome Measures: The change of average daily Area Under the Curve (AUC) of serum sodium by day 4 and 7 comparing with baseline serum sodium level within the double-blind therapy period;   Percentage of patients with normalized serum sodium at Day 4;   Percentage of patients with normalized serum sodium at Day 7;   Time to first normalization in serum sodium;   Change from baseline in serum sodium at Day 4;   Change from baseline in serum sodium at Day 7;   Percentage of patients requiring fluid restriction at any time during the double-blind therapy period of the study;   24-hour urine output;   Change from baseline in body weight (hypervolemic patients only);   Fluid balance (hypervolemic patients only);   The percentage of patients who are designated as treatment failure due to the need for saline infusion, with or without fluid restriction;   For CHF patients, improvement of symptoms and relevant physical examination measures;   For hepatic edema patients, improvement of symptoms and relevant physical examination measures or ultrasound test findings
11 Unknown  The Efficacy of Oral Versus Intravenous Hypertonic Saline Administration in Runners With Exercise-Associated Hyponatremia
Condition: Exercise-associated Hyponatremia
Interventions: Other: Intravenous hypertonic Saline;   Other: Oral hypertonic saline
Outcome Measure: Blood sodium concentration post administration of oral or IV hypertonic saline.
12 Recruiting Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia
Conditions: Liver Cirrhosis;   Hyponatremia
Intervention: Drug: Tolvaptan(OPC-41061)
Outcome Measures: the proportion of subjects with normal serum sodium level (135-145 mmol/l);   change in sodium level from baseline;   quality of life (EQ-5D-3L);   change in body weight;   edema;   renal function;   mortality and liver-related complications
13 Recruiting Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia
Condition: Hyponatremia
Intervention:
Outcome Measures: Accuracy of volume status measured by bioimpedance spectroscopy;   Laboratory data and echocardiography
14 Recruiting Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure.
Condition: Heart Failure With Hyponatremia
Intervention: Drug: Tolvaptan
Outcome Measure: Average daily AUC of change from baseline in serum Na level to day 4 within the double-blind treatment period
15 Unknown  Pseudohyponatremia of Multiple Myeloma is True Hyponatremia
Condition: Hyponatremia of Multiple Myeloma
Intervention: Other: blood test
Outcome Measures: hyponatremia present or not;   hyponatremia
16 Not yet recruiting Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
Condition: Hyponatremia
Intervention: Drug: Tolvaptan
Outcome Measures: Change in serum sodium concentration.;   Overly rapid increase in serum sodium.;   Percentage of subjects requiring rescue medication.
17 Recruiting Hyponatremia and Myometrium Contractility. An Invitro Study
Condition: Hyponatremia
Intervention:
Outcome Measure: Contractility
18 Recruiting The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia
Conditions: Heart Failure;   Hyponatremia
Intervention: Other: Fluid restriction
Outcome Measures: Change in plasma sodium from day 1 to day 4: - Normalization of plasma sodium or - A significant change in plasma sodium of a minimum of 5 mmol/L from baseline to day 4;   Change in plasma vasopressin and copeptin;   Change in blood pressure, heart rate, weight and oedemas;   Change in dyspnoea assessed by the patient;   Number of days until clinical stability;   The correlation between hospitalization time and plasma sodium;   Correlation between fluid restriction and change in kidney function;   Patient assessment of fluid restriction;   Patient compliance to fluid restriction
19 Recruiting Postoperative Hyponatremia - Are There Gender Differences?
Condition: Hyponatremia
Interventions: Procedure: Fluid administration;   Procedure: Perioperative fluid management based on Lean Body Mass
Outcome Measure: Change between preoperative and postoperative plasma sodium concentration
20 Not yet recruiting Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
Conditions: Hyponatremia;   Ascites
Interventions: Drug: Tolvaptan;   Drug: placebo
Outcome Measures: the change in the average daily area under the curve (AUC) for the serum sodium concentration from baseline to day 28 after intervention;   the change in the average daily area under the curve (AUC) for the serum sodium concentration from baseline to day 4;   the time to normalization of the serum sodium concentration;   the time to first paracentesis, number of paracentesis, the volume of ascitic fluid obtained from paracentesis;   Abdominal discomfort based on a 100-mm visual analogue scales (VAS);   The change in the dose of concomitant diuretics from baseline at day 28;   the number of participants with serious adverse events;   the time to ascites improvement;   the time of worsening of ascites